Reform

ReForm Therapeutics is a biopharmaceutical company dedicated to enhancing the delivery and stability of biologic medicines through advanced formulation technology. The company's proprietary platform employs a library of small molecule excipients that reduce the viscosity of highly concentrated protein solutions, facilitating the transition from intravenous to subcutaneous administration. Formerly known as ReForm Biologics, the company shifted its strategy in 2022 to develop an internal pipeline focused on rare diseases and high-need indications. Its lead candidate, RFT-001, is a novel formulation designed to treat calciphylaxis by addressing calcium deposits in the skin and vasculature. ReForm continues to leverage its technology through strategic collaborations with global pharmaceutical partners to optimize their biologic portfolios.